^
    Apply
    Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) (LANDSCAPE 1011) (NCT04585815)
    Phase 1/2
    Pfizer
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    11/10/2020
    Primary completion :
    05/17/2023
    Completion :
    06/17/2024
    PD-L1
    |
    BRAF V600E • BRAF V600
    |
    Mektovi (binimetinib) • Braftovi (encorafenib) • Inlyta (axitinib) • sasanlimab (PF-06801591) • SEA-TGT